TD
Toronto Dominion Bank
stockNYSE

Your numbers are off but I do agree it’s undervalued. TD Cowen puts Macy's real estate at $7.5 billion to $11.6 billion, while JPMorgan values it at $8.5 billion. Compare that with an enterprise value of roughly $9.7B (about $6.5B market cap plus net debt). The market is pricing the operating business, including Bloomingdale's and the credit card income, at close to zero on top of the real estate.

Im using Think or Swim but its crazy slow on closing trades. I cant tell you how many times ive had to cancel and re-dd close orders cause it wont close my positions. Like I said im losing profits cause its every trade. Its been like this for 3 yrs or whatever how long since TD Ameritrade went away.

here's the daily look at small-cap offerings priced on tuesday november 10, pulled from the sec filings. a 424B4 is the final prospectus for a fresh stock or unit offering, and a 424B5 (the final prospectus filed when shares are sold off a shelf registration) covers deals where a company sells stock it already registered earlier. the full list of 8 is posted separately below, so this is just the context before you dig in. **Aptera Motors Corp. ($SEV)**, Reasonable best efforts public offering of Class B common stock under an effective S-3 shelf, with concurrent private placement of warrants (Ladenburg Thalmann lead placement agent, StoneX co-placement agent) (424B5) 3,428,571 shares of Class B common stock at public offering price $1.75 per share; total offering price $5,999,999.25; placement agent fees $0.123 per share, total $419,999.95 (cash fee of 7.0% of gross proceeds); proceeds before expenses to us $1.63 per share, total $5,579,999.30; private placement warrants to purchase up to 3,428,571 shares of Class B common stock at exercise price $2.05 per share, exercisable on or after November 10, 2026, expiring five and one-half years from initial exercise date; placement agent warrants to purchase up to 102,857 shares of Class B common stock at exercise price $2.1875 per share; last reported sale price $2.28 on November 9, 2026 worth checking: read the use of proceeds and any warrant or conversion terms before the next session [filing](https://www.sec.gov/Archives/edgar/data/1786471/0001493152-26-051029.txt) **JIADE LIMITED ($JDZG)**, Registered offering (424B5 prospectus supplement) of Class A ordinary shares and pre-funded warrants, plus an investor option to buy additional shares or pre-funded warrants (424B5) 550,000 Class A Ordinary Shares at US$0.18 per share; pre-funded warrants for up to 6,116,666 Class A Ordinary Shares at US$0.179 per pre-funded warrant, exercise price US$0.001 per share; investor option for up to 6,666,666 additional Class A Ordinary Shares (or pre-funded warrants in lieu thereof). Gross proceeds not stated in the excerpt. worth checking: Pre-funded warrants (6,116,666 shares) far exceed the 550,000 common shares; confirm total gross proceeds, use of proceeds, and remaining shelf capacity in the full filing. [filing](https://www.sec.gov/Archives/edgar/data/1976908/0001104659-26-124977.txt) **Lichen International Ltd ($LICN)**, Unit offering (reasonable best efforts, placement agent Univest Securities, LLC) of Class A ordinary shares or pre-funded warrants, each paired with an ordinary warrant (424B5) 17,500,000 units at US$0.20 per Share-based Unit; US$3,500,000 aggregate gross proceeds; combined price for a Pre-Funded Warrant and Ordinary Warrant is US$0.19; Ordinary Warrants exercisable at US$0.20 cash per share, or zero-price exercise for 4.72 Class A ordinary shares per warrant; 82,600,000 shares underlying Ordinary Warrants assuming zero-price exercise; 100,100,000 aggregate underlying shares; last reported price US$0.4911 on November 9, 2026 worth checking: Dilution from the 4.72x zero-price warrant exercise (82,600,000 underlying shares versus 17,500,000 units), the company's CSRC post-closing filing requirement within three business days, and the remaining shelf capacity under registration no. 333-291878 [filing](https://www.sec.gov/Archives/edgar/data/1876766/0001185185-26-005284.txt) **National Healthcare Properties, Inc. ($NHP)**, At-the-market (ATM) equity offering program of common stock through sales agents, principals and forward sellers, with possible forward sale agreements, under shelf Registration No. 333-298131 (424B5) Up to $300,000,000 aggregate gross sales price of common stock ($0.01 par value); commission up to 2.0% of gross sales price; forward seller commission up to 2.0% in the form of a reduction to the initial forward sale price; last reported sale price $15.95 per share on November 9, 2026; number of shares not stated worth checking: Market cap is not stated in the filing, so confirm the company's size; then check remaining capacity on the shelf and the forward sale agreements, including settlement timing and dilution. [filing](https://www.sec.gov/Archives/edgar/data/1561032/0001140361-26-043057.txt) **Neuronetics, Inc. ($STIM)**, Preliminary prospectus supplement for a public offering of common stock (Nasdaq Global Market). Lead bookrunner William Blair; additional bookrunners BTIG and Canaccord Genuity. Underwriters have a 30-day option to buy additional shares from the company. (424B5) Share count, public offering price, underwriting discounts and proceeds are blank in this preliminary filing. Last reported sale price on Nov 9, 2026: $2.18 per share. 77,728,311 shares outstanding as of Sept 30, 2026. Perceptive Facility outstanding principal: $65 million as of Sept 30, 2026, interest rate 11.5%. Directors and related persons have indicated interest in buying shares at the public offering price, not binding. worth checking: Get the final pricing terms (share count, price, net proceeds) from the final 424B prospectus, then confirm the Perceptive Sixth Amendment prepayment (at least $15,000,000) is satisfied by Nov 30, 2026 or it terminates. [filing](https://www.sec.gov/Archives/edgar/data/1227636/0001193125-26-455694.txt) **Pacific Biosciences of California, Inc. ($PACB)**, At-the-market equity offering of common stock through sales agent Allen & Company LLC (S-3ASR shelf, filed 424B5) (424B5) Up to $100,000,000 aggregate offering price of common stock; commission up to 3% of gross proceeds; assumed 42,372,881 shares at $2.36 per share (last reported sale price on Nasdaq on November 9, 2026) for aggregate gross proceeds of approximately $100 million; assumed immediate dilution of $3.20 per share; 312,236,834 shares outstanding as of September 30, 2026 worth checking: Allen & Company is not required to sell any specific amount, so the 42,372,881-share figure is an assumption, not a commitment; confirm use of proceeds and remaining capacity under the shelf. [filing](https://www.sec.gov/Archives/edgar/data/1299130/0001104659-26-125153.txt) **PepGen Inc. ($PEPG)**, Underwritten public offering (shelf takedown under Form S-3, File No. 333-296016) of common stock and pre-funded warrants, with a 30-day underwriter option; preliminary, subject to completion (424B5) Aggregate offering shown on cover: $125,000,000. Number of shares and pre-funded warrants offered: blank. Public offering price per share and per pre-funded warrant: blank. Closing sale price on Nov 10, 2026: $4.61 per share. Pre-funded warrant price equals the offering price minus $0.0001, which is the warrant exercise price. Pre-funded warrants do not expire. Underwriting discounts, proceeds, and over-allotment amount ($ million, blank): not stated. Joint bookrunners: Leerink Partners, Stifel, Guggenheim Securities. worth checking: Final 424B5 pricing: the share count, offering price and over-allotment amount are blank in this preliminary version, so confirm them against the final supplement and the use of proceeds section. [filing](https://www.sec.gov/Archives/edgar/data/1835597/0001193125-26-455711.txt) **Prime Medicine, Inc. ($PRME)**, Public offering of common stock (preliminary prospectus supplement, shelf registration No. 333-291348, underwriters Jefferies, TD Cowen, Goldman Sachs & Co. LLC) (424B5) $125,000,000 of common stock; public offering price per share and total not stated (blanks); underwriters option to purchase up to an additional $18,750,000 of shares within 30 days; closing price on November 9, 2026 was $4.30 per share on The Nasdaq Global Market; no warrants stated worth checking: Get the final 424B5 for the blank per-share price, share count and net proceeds, confirm whether the $18,750,000 greenshoe was exercised, and check remaining shelf capacity under the March 3, 2026 prospectus. [filing](https://www.sec.gov/Archives/edgar/data/1894562/0001628280-26-072802.txt) the usual reminder: this is education and filing reading, not a signal to buy or sell anything, and dilution and pricing details are in the prospectus itself. when you look through these, which part of the filing do you check first, the use of proceeds or the dilution table?

BlackBerry announced today that members of its management team will participate in the following upcoming investor conferences: BMO Technology and Innovation Leaders Conference - November 12, 2026, New York, NY Grant Courville, Senior Vice President, Products and Strategy, QNX, will participate in one-on-one meetings with institutional investors. No formal presentation or webcast is scheduled.RBC Capital Markets Global TIMT Conference - November 17, 2026, New York, NY Tim Foote, Chief Financial Officer, and John Wall, President of QNX, will participate in a fireside chat beginning at 2:40 p.m. ET, as well as meetings with institutional investors. 18th Annual TD Cowen Canadian Technology Conference - November 24, 2026, Toronto, Ontario Tim Foote, Chief Financial Officer, and John Wall, President of QNX, will participate in a fireside chat beginning at 3:00 p.m. ET, as well as meetings with institutional investors. Live webcasts of the RBC Capital Markets and TD Cowen fireside chats will be available on BlackBerry's investor relations website at BlackBerry.com/Investors. Replays will be available following each event.

I’m autistic, I know what it’s like to struggle to communicate. I’m just lucky I have a few decades in engineering, science, and philosophical training and peer-reviewed publications. Helping people refine what they understand and how they communicate is a big part of my job now. I like TD. He’s interested in the right things, he just needs some hubris and self awareness.

BN, BRK.B, TD

Selling TD to Schwab ruined my TD experience. I have been with them since 2001.

Ethereum is one blockchain, they are not the center of the blockchain technology because their token is 2nd in market cap. All of these are blockchain/smart contract based projects that involve central banks, monetary authorities and other institutions. Theres also many more than this. |Initiative|Institutions involved|What they are testing| |:-|:-|:-| |Project Agorá|BIS, 8 central banks, 40+ financial institutions|Tokenised central-bank reserves and commercial-bank deposits on a shared programmable platform.| |Project mBridge|BIS, HKMA, PBOC, Bank of Thailand, UAE Central Bank, Saudi Central Bank|Multi-CBDC cross-border payments and settlement using DLT.| |Project Mariana|BIS, Banque de France, MAS, Swiss National Bank|Wholesale CBDC trading, cross-border settlement, automated market makers and interoperability.| |Project Dunbar|BIS, Reserve Bank of Australia, MAS, Bank Negara Malaysia, South African Reserve Bank|Shared multi-CBDC settlement infrastructure.| |Project Helvetia|Swiss National Bank, SIX, financial institutions|Tokenised securities settlement using wholesale CBDC and central-bank money.| |Project Ensemble|HKMA, HSBC, Standard Chartered, Bank of China, BlackRock and others|Tokenised deposits, tokenised assets and settlement in tokenised central-bank money.| |Project Samara|Bank of Canada, RBC, TD, EDC|Tokenised bond issuance, trading, lifecycle management and settlement using central-bank money.| |Project Cedar|New York Fed, New York Innovation Center|Blockchain-based wholesale cross-border payment infrastructure.| |Project Jasper|Bank of Canada, Payments Canada and financial institutions|DLT-based payments and securities settlement.| |Project Meridian|BIS, Bank of England|Synchronising central-bank payments with asset transfers on separate ledgers.| |Project Promissa|BIS, Swiss National Bank, World Bank, IMF observer|Tokenisation of government promissory notes used to fund multilateral development banks.| |Project Icebreaker|BIS, Bank of Israel, Norges Bank, Sveriges Riksbank|Interoperability between domestic CBDC systems for international payments.| |Project Atlas|BIS, Deutsche Bundesbank, De Nederlandsche Bank|Using public blockchain and exchange data to measure cryptoasset flows and DeFi activity.|

This question is all about the ability to control your allocation. How much control do you want, and how much fine tuning do you want to be able to do? I like VTI+VXUS. I want to be able to choose my international allocation. VT is fine if you don't want to do the yearly rebalance. For even less control of your allocation (but more ease and less work for you), choose a TD fund and let Vanguard (or Fidelity or Schwab) do all the work.

Been using Metrobank TDs for more than a year ..now that they have 6% for 6 mos,better na sila than Maya TD..I also have Maya TD but problem lang with Maya is the customer support..with Metrobank, your bank manager can assist you with your online TD account as well ..